Radionuclide imaging of myocardium using technetium (99m-Tc) sestamibi with cardiac stress test

The recommended dose is a single injection of 400 micrograms regadenoson into a peripheral vein, with no dose adjustment necessary for body weight.

Patients should avoid consumption of any products containing methylxanthines (e.g. caffeine) as well as any medicinal products containing theophylline for at least 12 hours before regadenoson administration.

When possible, dipyridamole should be withheld for at least two days prior to regadenoson administration.

Aminophylline may be used to attenuate severe and/or persistent adverse reactions to regadenoson but should not be used solely for the purpose of terminating a seizure induced by regadenoson.

Regadenoson causes a rapid increase in heart rate. Patients should remain sitting or lying down and be monitored at frequent intervals after the injection until the ECG parameters, heart rate and blood pressure have returned to pre-dose levels.

Repeated use

This product is to be administered only once within a 24 hour period. Safety and tolerability of repeated use of this product within 24 hours has not been characterised.

• Regadenoson should be administered as a rapid, 10-second injection into a peripheral vein using a 22-gauge or larger catheter or needle.
• 5 ml of sodium chloride 9 mg/ml (0.9%) solution for injection should be administered immediately after the injection of regadenoson.
• The radiopharmaceutical for the myocardial perfusion imaging agent should be administered 10-20 seconds after the sodium chloride 9 mg/ml (0.9%) solution for injection. The radiopharmaceutical may be injected directly into the same catheter as regadenoson.